Avid Radiopharmaceuticals

Avid Radiopharmceuticals Clinical Trials

In 2011, Dr. John H. Fullerton, who leads The Clinical Research Division of Hampton Health, Ltd.™, was chosen to be an investigator in the widely anticipated clincial trials of AVID Radiopharmaceuticals (18F-AV-45-A17 Study) conducted by Health Diagnostics of California, LLC with Dr. Stephen R. Bunker (one of the foremost imaging diagnosticians in the world). Hampton Health, Ltd.™ ranked 7th place for participant qualification and enrollment in this large multi-center study that involved 18 sites nationally.

On May 24th 2012 Dr. Fullerton was interviewed by KTVU Channel 2 News regarding the Clinical Trials of Avid Radiopharmaceuticals, "some calling it the holy grail of Alzheimer's Research" as reported by Channel 2.

The AVID study (18F-AV-45-A17) focused on respondents age 50 and above who experienced some form of memory loss, (including MCI – Mild Cognitive Impairment), to become part of a compensated study which utilized a specifically designed PET scan (with the addition of the unique radiopharmaceutical compound Amyvid™ or florbetapir F 18) for the augmented detection of Alzheimer's Disease and read by Dr. Stephen R. Bunker.

Avid Radiopharmaceuticals, Inc., a privately held company developing novel molecular imaging compounds intended for the detection and monitoring of chronic human diseases, was acquired by Eli Lilly and Company in December of 2010.